BCYC250117C12500
- 1.50
- -1.50-50.00%
Bicycle Therapeutics Newsroom
Bicycle Therapeutics Is Maintained at Market Outperform by JMP Securities
JMP Securities Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Cuts Target Price to $26
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Incyte (INCY) and Bicycle Therapeutics (BCYC)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (ZTS), Walgreens Boots Alliance (WBA) and Bicycle Therapeutics (BCYC)
H.C. Wainwright Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Cuts Target Price to $33
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Bicycle Therapeutics (BCYC) and Quest Diagnostics (DGX)
Barclays Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $40
Morgan Stanley Maintains Bicycle Therapeutics(BCYC.US) With Hold Rating, Maintains Target Price $30
Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Cuts Target Price to $32
B. Riley Securities Maintains Neutral on Bicycle Therapeutics, Lowers Price Target to $17
Bicycle Therapeutics Analyst Ratings
Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $38
Bicycle Therapeutics Initiated at Equal-Weight by Stephens & Co.
Bicycle Therapeutics Analyst Ratings
Stephens Initiates Bicycle Therapeutics(BCYC.US) With Hold Rating, Announces Target Price $25
Morgan Stanley Initiates Bicycle Therapeutics(BCYC.US) With Hold Rating, Announces Target Price $30
JMP Securities Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $32
Barclays Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $55
RBC Capital Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $35